MA40996A - Matériaux et procédés de traitement d'un dysfonctionnement endothélial et procédés de surveillance de l'efficacité du traitement chez un patient - Google Patents
Matériaux et procédés de traitement d'un dysfonctionnement endothélial et procédés de surveillance de l'efficacité du traitement chez un patientInfo
- Publication number
- MA40996A MA40996A MA040996A MA40996A MA40996A MA 40996 A MA40996 A MA 40996A MA 040996 A MA040996 A MA 040996A MA 40996 A MA40996 A MA 40996A MA 40996 A MA40996 A MA 40996A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- methods
- effectiveness
- patient
- monitoring
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462080984P | 2014-11-17 | 2014-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40996A true MA40996A (fr) | 2017-09-26 |
Family
ID=56014411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040996A MA40996A (fr) | 2014-11-17 | 2015-11-12 | Matériaux et procédés de traitement d'un dysfonctionnement endothélial et procédés de surveillance de l'efficacité du traitement chez un patient |
Country Status (11)
Country | Link |
---|---|
US (1) | US20170360837A1 (fr) |
EP (2) | EP3221697B1 (fr) |
JP (1) | JP2018503802A (fr) |
KR (1) | KR102626288B1 (fr) |
AU (1) | AU2015350250A1 (fr) |
BR (1) | BR112017010313B1 (fr) |
CA (1) | CA2968222A1 (fr) |
ES (1) | ES2935903T3 (fr) |
MA (1) | MA40996A (fr) |
WO (1) | WO2016081309A1 (fr) |
ZA (1) | ZA201704110B (fr) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7113986B2 (en) | 2000-07-14 | 2006-09-26 | Business Signatures Corporation | System and method for modeling information system capacity and accepting sessions in an information system |
US8617538B2 (en) * | 2009-09-28 | 2013-12-31 | Board Of Regents Of The University Of Texas System | Mesodermal-like cell population for treating ischemia in mammals |
EP2611906B1 (fr) * | 2010-08-31 | 2024-01-03 | Gallant Pet, Inc. | Thérapies systémiques par cellules souches allogéniques pour le traitement des maladies chez les chats et les chiens |
-
2015
- 2015-11-12 MA MA040996A patent/MA40996A/fr unknown
- 2015-11-13 EP EP15861319.0A patent/EP3221697B1/fr active Active
- 2015-11-13 BR BR112017010313-3A patent/BR112017010313B1/pt active IP Right Grant
- 2015-11-13 ES ES15861319T patent/ES2935903T3/es active Active
- 2015-11-13 US US15/527,270 patent/US20170360837A1/en not_active Abandoned
- 2015-11-13 AU AU2015350250A patent/AU2015350250A1/en not_active Abandoned
- 2015-11-13 CA CA2968222A patent/CA2968222A1/fr not_active Abandoned
- 2015-11-13 EP EP22208663.9A patent/EP4190917A1/fr active Pending
- 2015-11-13 WO PCT/US2015/060624 patent/WO2016081309A1/fr active Application Filing
- 2015-11-13 KR KR1020177016542A patent/KR102626288B1/ko active IP Right Grant
- 2015-11-13 JP JP2017526979A patent/JP2018503802A/ja active Pending
-
2017
- 2017-06-15 ZA ZA2017/04110A patent/ZA201704110B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2018503802A (ja) | 2018-02-08 |
EP3221697B1 (fr) | 2022-11-23 |
CA2968222A1 (fr) | 2016-05-26 |
AU2015350250A1 (en) | 2017-06-29 |
WO2016081309A1 (fr) | 2016-05-26 |
ES2935903T3 (es) | 2023-03-13 |
EP3221697A4 (fr) | 2018-04-11 |
KR20170083624A (ko) | 2017-07-18 |
EP3221697A1 (fr) | 2017-09-27 |
ZA201704110B (en) | 2018-05-30 |
BR112017010313B1 (pt) | 2024-01-23 |
EP4190917A1 (fr) | 2023-06-07 |
KR102626288B1 (ko) | 2024-01-16 |
BR112017010313A2 (pt) | 2017-12-26 |
US20170360837A1 (en) | 2017-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42819A (fr) | Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae | |
MA51348A (fr) | Dispositif et procédé permettant d'attirer et de piéger des insectes volants | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA40008A (fr) | Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie | |
MA50849A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
FR3016699B1 (fr) | Procede et dispositif pour la detection notamment de defauts refractants | |
SG11201702319VA (en) | Air filter ultrasonic cleaning systems and the methods of using the same | |
MA40921A (fr) | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation | |
IL249630A0 (en) | Methods for dealing with vulnerabilities and methods for warning using ultrasound | |
MA45865A (fr) | Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1 | |
FR3023938B1 (fr) | Traitement des messages d'alarmes et de maintenance d'un aeronef | |
EP3134079A4 (fr) | N-(2-amino)-2-oxoétriylbenzamides substitués en tant qu'inhibiteurs d'autotaxine | |
FR3025792B1 (fr) | Dispositif de traitement d'effluents salins sursatures en presence d'inhibiteurs de precipitation | |
FR3026008B1 (fr) | Composition a base de particules composites spheriques multicouches et d'un filtre uv | |
PL3105366T3 (pl) | Zastosowanie kwasu fosfowinowego i jego soli do traktowania wody w układach prowadzących wodę | |
FR3020951B1 (fr) | Association d'un tetrapeptide et d'un glyceryl ester pour le traitement de l'alopecie androgenique. | |
HUE056873T2 (hu) | Oldatok a propikonazol hatékonyságának fokozására az élõ növényeken és kapcsolódó módszerek | |
MA40904A (fr) | Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie | |
FR3011110B1 (fr) | Methode de suivi et d'aide a l'observance du traitement d'un patient | |
MA40869A (fr) | Combinaisons pharmaceutiques de vildagliptine et d'agonistes de ppar | |
ES2660372T8 (es) | Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington | |
SG11201606546VA (en) | Antibodies to matrix metalloproteinase 9 and methods of use thereof | |
MA40996A (fr) | Matériaux et procédés de traitement d'un dysfonctionnement endothélial et procédés de surveillance de l'efficacité du traitement chez un patient | |
IL251024A0 (en) | Antibodies against eutaxin 2 for use in the treatment of liver diseases | |
PL3633122T3 (pl) | Przyrząd do wspomagania montażu i demontażu ogrodzeń pastwiskowych |